ProMIS Neurosciences (PMN)

PMN Misfolded Protein ALS/AD

BiotechSign Signal Grade

F
Signal Grade
13.4/100 composite signal score

Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.

Insider Buying
0
Publications
100
Dilution Risk
56
Clinical Activity
4
Short Interest
30

Pipeline Overview

Therapeutic Focus
Misfolded Protein ALS/ADsrc

Clinical Trial Activity

1
Clinical Trial
(ClinicalTrials.gov aggregate)
1 Phase 1
Trial Phase Breakdown
5
PubMed Publications
0
Catalyst Records

ClinicalTrials.gov aggregate as of 2026-09-28. ClinicalTrials.gov

Dilution Risk

HIGH DILUTION RISK
21.3 months
Cash Runway Estimate
56/100
Dilution Score
9,340,131
Outstanding Warrants
90Warrant Risk
35Convertible Risk
52Offering Ability

Dilution score: 56/100 (HIGH), 21.3 months cash

Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score

Short Interest

5.21%
Float Shorted
4.8
Days to Cover
MODERATE
Squeeze Risk
-9.0%
SI Change
DECREASING
Trend
240,000
Shares Short

Short interest: 5.21% of float, squeeze risk: MODERATE

FINRA short sale data. FINRA short interest

Recent News & SEC Filings

Headlines from public sources. BiotechSign does not endorse or verify linked content.

Recent Publications

Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for ProMIS Neurosciences.

Full PMN Dashboard Sign Up Free

Primary Sources

This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.